middle.news
Neuren’s DAYBUE Set to Hit US$700m Sales by 2028 with New US and Global Growth
10:42am on Wednesday 14th of January, 2026 AEDT
•
Healthcare
Read Story
Neuren’s DAYBUE Set to Hit US$700m Sales by 2028 with New US and Global Growth
10:42am on Wednesday 14th of January, 2026 AEDT
Key Points
DAYBUE global net sales forecast to reach ~US$700 million by 2028
Over 2,000 Rett syndrome patients treated in the US since 2023 launch
New DAYBUE STIX powder formulation launching fully by Q2 2026 in the US
DAYBUE oral solution approved in Israel, with Japan Phase 3 trial results expected late 2026/early 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE